Analysts Offer Insights on Healthcare Companies: OrganiGram Holdings (OGI) and Qiagen (QGEN)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on OrganiGram Holdings (OGI – Research Report) and Qiagen (QGEN – Research Report) with bullish sentiments.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
OrganiGram Holdings (OGI)
In a report released yesterday, Neal Gilmer from Haywood maintained a Buy rating on OrganiGram Holdings, with a price target of C$3.25. The company’s shares closed last Wednesday at $1.38.
According to TipRanks.com, Gilmer is ranked #10012 out of 12109 analysts.
OrganiGram Holdings has an analyst consensus of Strong Buy, with a price target consensus of $2.48, which is an 83.7% upside from current levels. In a report issued on February 10, Alliance Global Partners also maintained a Buy rating on the stock with a C$4.00 price target.
See today’s best-performing stocks on TipRanks >>
Qiagen (QGEN)
Jefferies analyst Tycho Peterson maintained a Buy rating on Qiagen today. The company’s shares closed last Wednesday at $49.03, close to its 52-week high of $49.30.
According to TipRanks.com, Peterson is a 4-star analyst with an average return of
Currently, the analyst consensus on Qiagen is a Moderate Buy with an average price target of $55.04, a 12.7% upside from current levels. In a report issued on February 6, Barclays also maintained a Buy rating on the stock with a $58.00 price target.
